Alpine Immune Sciences Stock News

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflamma

Alpine Immune Sciences, Inc. (NASDAQ:ALPN)s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.44 and traded as high as $14.20. Alpine Immune Sciences shares last traded at $13.95, with a volume of 557,035 shares. Separately, Zacks Investment Research raised shares of Alpine []

(RTTNews) - Alpine Immune Sciences, Inc. (ALPN) and Horizon Therapeutics plc (HZNP) announced a license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine''s discovery platform. The agreement includes licensing of a lead, potential first-in-class preclinical candidate,

State Street Corp acquired a new stake in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 173,119 shares of the biotechnology companys stock, valued at approximately $1,558,000. State Street Corp owned approximately 0.72% of Alpine Immune Sciences []

Alpine Immune Sciences (NASDAQ:ALPN) was upgraded by Zacks Investment Research from a strong sell rating to a hold rating in a research report issued on Monday, Zacks.com reports. According to Zacks, Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of []

Northern Trust Corp boosted its holdings in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) by 470.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 113,579 shares of the biotechnology companys stock after acquiring an additional 93,666 shares during the quarter. []

Equities research analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will announce earnings of ($0.49) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Alpine Immune Sciences earnings, with estimates ranging from ($0.58) to ($0.44). Alpine Immune Sciences reported earnings per share of ($0.27) in the same quarter []

Activists file with the SEC on Bird Global, Janus Henderson Group, Alpine Immune Sciences, and Hain Celestial Group

Analysts forecast that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will report sales of $8.26 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Alpine Immune Sciences earnings. The lowest sales estimate is $5.29 million and the highest is $10.00 million. Alpine Immune Sciences reported sales of $5.64 million in the []

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory

Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2021 Results - Earnings Call Transcript

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -58.62% and 9.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the s